Psoriasis

New research finds salivary antioxidants and oxidative stress could be important biomarkers for plaque psoriasis.

In a meta-analysis comparison of biologics and oral treatments for moderate to severe plaque psoriasis, results suggest that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with the highest response rates in both short-term and long-term therapy.

Researchers exhibit recent advances in the basic characteristics of interleukin (IL)-24, a member of the IL-20 family of cytokines associated with pro-inflammatory autoimmune disorders such as psoriasis, arthritis, and inflammatory bowel diseases, as a catalyst in the pathogenesis of allergic skin inflammation.

A formulation of calcipotriene and betamethasone dipropionate cream met its primary endpoint for treating plaque psoriasis during its phase 3 trial in the European Union, according to an announcement from MC2 Therapeutics.

Researchers outline the significant role IL-37 plays in psoriasis, and other skin and connective tissue diseases, suggesting the need for further research, according to a review.

Compared with other biologics approved for psoriasis treatment, excluding recently approved biologics, ixekizumab and brodalumab were shown to have greater cumulative clinical benefit for patients with psoriasis, according to study findings.

Researchers outlined a comprehensive review of the common mechanisms through which interleukin-17 (IL-17) is considered a molecular target for developing novel biological therapies in several different fields of medicine, according to report findings.

While prevalence rates of psoriasis are lower among the Latino population compared with the white and black populations in the United States, Latinos are shown to be disproportionately affected by poorer quality of life and intensified disease severity, according to study findings.

The researchers said that they are the first to demonstrate elevated concentrations of serum fibroblast growth factor 21 (FGF21) in patients with plaque-type psoriasis.

A recently published review in Frontiers in Immunology highlights the efficacy of Janus kinase inhibitors as treatments for several dermatological ailments, including psoriasis. Authors described how newly researched pathologic factors have changed therapeutic practices used to treat inflammation and autoimmunity.

Current categories of classifying psoriasis, such as mild, moderate, or severe, do not consider past treatments or involvement of special areas, leading to undertreatment, a report said.

The investigational therapy, an interleukin (IL)-17A and IL-17F inhibitor, is the third phase 3 study of bimekizumab to report positive results since October, following BE VIVID and BE READY, which evaluated the safety and efficacy of the drug.

More treatments are needed for the 100 million individuals worldwide affected by psoriasis. Researchers from Brigham and Women's Hospital and the Harvard Stem Cell Institute have discovered a possible source of the skin thickening that may be triggered by dysregulated stem cells.

The link connecting gut bacteria and psoriasis is inflammation, the authors said.

There are significant sex differences in links between psoriasis and metabolic disorders, according to a study published this week.

Two recent studies have explored the role of activator protein-1 (AP-1), a transcription factor with a role in skin diseases caused by inflammation, including psoriasis and atopic dermatitis

Researchers used ultrasound to investigate the anatomical basis for arthralgia symptoms and found that tenosynovitis was the only significant difference in patients who went on to develop psoriatic arthritis (PsA).

Without information about the possible severity of their condition, patients with psoriasis may not adhere to treatment, which could lead to worse outcomes.

BE READY is designed to evaluate the safety and efficacy of bimekizumab, humanized monoclonal IgG1 antibody that targets and neutralizes interleukin- (IL-)17A and IL-17F, a pair of cytokines that propel the inflammatory process through their effects on other messengers in the body that trigger chronic inflammatory response.

Genetics plays a strong role in the the trajectory of the how psoriatic arthritis manifests in joint arthritis compared with skin disease.

A recent study in the International Journal of Women’s Dermatology described the complex interplay of sex hormones in the pathways of metabolic syndrome (MetS) in pre- and postmenopausal women and how clinicians should be aware of the multiple factors of MetS.

The age of psoriasis onset determines whether arthritis or psoriasis starts first in patients with psoriatic arthritis (PsA).

Authors led by Justin Carrico of RTI Health Solutions compared 9 different biologics and the oral drug apremilast in treatment of psoriasis; their anaylsis, “from a US health plan’s perspective,” involved both base cost and cost-effectiveness models that included adverse events.

Crowley and colleagues presented the 4-year results from reSURFACE 1 at the 28th European Academy of Dermatology and Venereology Congress, held October 9-13, 2019 in Madrid, Spain.